NSAID Panel Could Give Naproxen Labeling Edge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.